1st Edition

Treatment and Prevention

ISBN 9789814316262
Published November 27, 2012 by Jenny Stanford Publishing
492 Pages 19 B/W Illustrations

USD $190.00

Prices & shipping based on shipping country


Book Description

In recent years, the understanding of the pathophysiological processes of atherosclerosis, a chronic inflammatory disease of the vessel wall being the leading cause for mortality in industrial countries, has tremendously increased. The feasibility of translating such knowledge to novel therapeutic approaches is currently being explored at various levels. This book highlights advances in atherosclerosis and links these to relevant therapeutic strategies. It compiles and details cutting-edge research in cardiovascular medicine from internationally renowned authors.

Table of Contents

Novel approaches in treatment of atherosclerosis, C Weber & O Soehnlein

Chemokines as therapeutic targets of atherosclerosis, RR Koenen & C Weber

MIF antagonism as a therapeutic approach to atherosclerosis. J Bernhagen & A Schober

Peptide-based vaccination strategies to promote Treg- or antibody-mediated atheroprotection, Z Mallat

Modulation of prostanoids in the treatment of atherosclerosis, JZ Haeggström

Stabilization of mast cells for taming vulnerable plaques, GP Shi & P Libby

HDL, ABC transporters, and cholesterol efflux as therapeutic targets in atherosclerosis, DJ Rader

Role of selective phospholipase A2 inhibition in the treatment of atherosclerosis, C MacPhee

Modulation of the rennin-angiotensin system in atherosclerosis, A Daugherty

Role of matrix metalloproteases as targets for the prevention of atherosclerosis, A Newby

Probucol-derivates in the treatment of atherosclerosis, R Stocker

Interference with apoptosis and ER stress in the treatment of atherosclerosis, I Tabas

MicroRNAs in the pathogenesis and therapy of atherosclerotic vascular disease, A Schober & C Weber

Neutrophils and their granule proteins in the treatment of atherosclerosis, O Soehnlein & C Weber

Platelets in the treatment of atherosclerosis, D Lievens & P von Hundelshausen

Costimulatory molecules in the treatment of atherosclerosis, E Lutgens & N Gerdes

View More



Christian Weber is Chair and Director of the Institute of Cardiovascular Prevention at the Ludwig-Maximilians University in Munich, Germany. After graduating in medicine and completing his training in internal medicine at Ludwig Maximilians University Munich, Germany, and at Harvard Medical School, Boston, USA, he was appointed Professor of Molecular Cardiology at RWTH Aachen University in 2001 and board-certified in clinical cardiology in 2004. Since 2006, he has had a joint appointment as a Professor at the Cardiovascular Research Institute Maastricht. His group is interested in molecular interactions and pathophysiological functions of chemokines and their receptors, adhesion molecules and immune cell subsets in vascular disease. His clinical interests are focused on the prevention of cardiovascular disease using biomarkers and genetic or cellular diagnostics. He is Fellow of the European Society of Cardiology, Editor-in-Chief of Thrombosis and Haemostasis and co-founder of Carolus Therapeutics.

Oliver Soehnlein is a group leader at the Institute of Cardiovascular Prevention at the Ludwig-Maximilians University in Munich, Germany. After having received his M.D. in 2004 from the Friedrich-Alexander University of Erlangen, Germany, he continued his research at Karolinska Institutet, Stockholm, Sweden, where he received his Ph.D. in Physiology in 2008. Thereafter, he was recruited to the RWTH Aachen University, Germany and in 2011 to the Ludwig-Maximilians University of Munich where he leads a junior research group focusing on the cellular interplay between myeloid cell subsets in acute and chronic inflammatory conditions.